Longboard Pharmaceuticals Inc Funding & Investors
San Diego, CA
Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.
longboardpharma.comTotal Amount Raised: $1,596,968
Longboard Pharmaceuticals Inc Funding Rounds
Post Ipo Equity
$1,072,300
Post Ipo Debt
$350,000
Post Ipo Debt
$174,668
IPO
Unknown
Funding info provided by Diffbot.